Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening  by Manjunatha, Ujjini H. & Smith, Paul W.
Bioorganic & Medicinal Chemistry 23 (2015) 5087–5097Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcPerspective: Challenges and opportunities in TB drug discovery from
phenotypic screeninghttp://dx.doi.org/10.1016/j.bmc.2014.12.031
0968-0896/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Tel.: +65 6722 2900; fax: +65 6722 2917.
E-mail addresses: manjunatha.ujjini@novartis.com (U.H. Manjunatha), paul.
smith@novartis.com (P.W. Smith).Ujjini H. Manjunatha ⇑, Paul W. Smith ⇑
Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore
a r t i c l e i n f oArticle history:
Received 29 October 2014
Revised 12 December 2014
Accepted 15 December 2014
Available online 24 December 2014
Keywords:
Tuberculosis
Mycobacterium
New chemical entities
Phenotypic screening
Drug discoverya b s t r a c t
Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly
prevalent. Hence there is an urgent need to discover new TB drugs. Cell based phenotypic screening
represents a powerful approach to identify anti-mycobacterial compounds and elucidate novel targets.
Three high throughput phenotypic screens were performed at NITD against mycobacterium. Hits were
identiﬁed and chemical series selected for optimisation. This produced compounds with good in vitro
anti-mycobacterial activity and pharmacokinetic properties. Some compounds displayed oral activity
in mouse efﬁcacy models of TB. Herein, we review the TB discovery efforts at NITD and share experiences
in optimisation of phenotypic hits, describing challenges encountered and lessons learned. We also offer
perspectives to facilitate future selection and advancement of phenotypic hits.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb),
continues to pose a major global health problem and multi-drug
resistant strains are becoming increasingly widespread.1 In 2013
there were over 9 million TB cases worldwide and over 1.5 million
deaths attributed to the disease. Nearly 4% of all new TB cases in
2010 were multi-drug resistant (MDR). The current ﬁrst line drugs
for TB (isoniazid, rifampicin, pyrazinamide and ethambutol) were
discovered decades ago and are increasingly becoming less useful
due to emerging resistance and synergistic interactions with HIV
AIDS patients. Furthermore, effective use of these drugs require
months of combination therapy, leading to issues with compliance
and signiﬁcant side effects. Thus, there is an urgent need to
discover new TB drugs. Over the past ten years there has been a
major investment by scientists from both academia and pharma-
ceutical companies into TB drug discovery and development.2
High-throughput screening (HTS) has become an integral part of
pharmaceutical research and fuelled drug discovery projects.3
Drug discovery screens can be either target or cell based/pheno-
typic. Each has advantages and disadvantages.4 The power of a tar-
get based strategy includes the ability to apply molecular and
chemical knowledge to investigate a speciﬁc molecular hypothesis
and ability to perform HTS against the target. The main limitationis that the molecular hypothesis or target may not be relevant in
the disease pathogenesis setting, thus placing a major emphasis
on target validation. In contrast, the strength of a phenotypic
approach is that the assay does not require knowledge of molecu-
lar mechanism of action; however in vitro HTS growth conditions
should mimic disease settings. The main drawback of this
approach is the challenge in optimizing hits with multi-parametric
cell based activity. The advantage of a phenotypic screen is the pos-
sibility to ﬁnd NCEs that inhibit new target/s or pathway/s, and the
potential to ﬁnd pro-drugs and other complex mechanisms of
action. All currently used antibiotics were discovered using cell
based phenotypic screening, highlighting the value of this
approach.
2. TB drug discovery at NITD
The Novartis Institute for Tropical Diseases (NITD) in Singapore
was established in 2002. The main objective of the TB program at
NITD was to develop new chemical entities (NCEs) active against
MDR-TB and extensively drug resistant (XDR) TB to enhance cure
rates and improve patient compliance. Both molecular target
screening and whole cell based phenotypic screening were pur-
sued to identify NCEs active against Mtb. A general target-based
and phenotypic cell based TB drug discovery ﬂow-chart is illus-
trated in Figure 1.
Target based Mtb HTS has been pursued extensively in the last
decade. During the early stages of the work at NITD, several well
deﬁned molecular targets (NAD synthase,5 pantothenate kinase,
Table 1
Target based biochemical screens pursued at NITD
Target enzyme (Rv number) Library size Hits Description/issues
Peptide deformylase6 (Rv0429c, PDF) Antibacterial PDF focussed library 200 Bacteriostatic
Limited in vivo mouse efﬁcacy
Dihydropteroate synthase (Rv3608c, DHPS) 1.3 million 3071 Coupled enzyme assay
Lack of cellular activity
Dihydrofolate reductase (Rv2763c, DHFR) Focussed library 100 Coupled enzyme assay
Low selectivity vs human DHFR
Low permeability
Pantothenate kinase (Rv1092c, PanK) 1.3 million 800 Lack of cellular activity
NAD (+) synthetase (Rv2438c, NadE) 2.2 million 300 Lack of tractable hits
Cell-growth inhibition 
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Figure 1. A typical molecular target-based and cell-based TB drug discovery cascade. (SAR, structure–activity relationship; SPR, structure–activity relationship; HTS, high
through-put screen; PoC, proof-of-concept in patients.)
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mylase6) were screened against the Novartis compound collection
or with focused libraries.7 However, these efforts (summarised in
Table 1), did not produce advanced leads. A few possible reasons
for the lack of success with the target based strategy are: lack of
chemical validation of the target, failure to ﬁnd tractable hits,~2.2 m cpds
Single pt @10μM
7H9 + glycerol
BTG readout 
~2.2M cpds
Single pt @10 μM; 
7H9 no glycerol; 
BTG readout
M. bovis BCG 2 days 
& 4 days exposure
16.3K hits
Mtb H37Ra 4 days 
exposure
14.5K new hits
2,258 hits
Single pt @ 10 μM 
7H9 no glycerol,
Absorbance (OD600); 
Mtb H37Rv;
inhibiton at least 
35%
~8K hits
Single pt @ 6.25 μM 
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BTG, Mtb H37Ra 
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2286 compounds
A
10 pt dose response;  
7H9 no glycerol,
Absorbance (OD600); Mtb H37Rv; 
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Campaign 1 and 2
A -
B –
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Figure 2. The 3 HTS phenotypic screening cinability to translate enzyme to cellular activity, etc.8 In the wider
anti-bacterial ﬁeld, target based approaches have also shown lim-
ited success and phenotypic screens identiﬁed more ﬁrst-in-class
molecules.9,10 Recent work highlighted the underlying complexity
of bactericidal activity by antibiotics and suggested discrete mech-
anisms distal to the actual molecular target leading to bacterialB
Summary of hit triaging in the 3 campaigns
MIC50 ranges of hits selected vs Mtb H37Rv
ampaigns and distribution of Mtb hits.
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towards phenotypic screening.
Recently several reviews have been published describing chal-
lenges and opportunities in TB drug discovery.12–18 In this perspec-
tive article, we describe the experiences and insights gained at
NITD from TB phenotypic screening and the subsequent optimiza-
tion of hits. It is anticipated that these learnings may assist others
in this challenging ﬁeld. We also offer a perspective to facilitate the
identiﬁcation and advancement of future hits.
3. High throughput screening campaigns
To minimise biosafety risks in handling large volumes of path-
ogenic Mtb cultures, M. bovis BCG and avirulent M. tuberculosis
H37Ra were used in BSL2 laboratory in HTS. The genome of M.
bovis BCG is >99% identical to Mtb H37Rv.19 Primary screening
against M. bovis BCG is a practical and viable approach to identify
NCEs active against Mtb.20,21 Conﬁrmed hits were followed up by
testing against Mtb H37Rv and MDR TB clinical isolates. The 3 phe-
notypic HTS campaigns were carried out over a 5 year period with
2.2 million Novartis compounds (details below and in Fig. 2). The
three campaigns generated a signiﬁcant number of primary hits
with anti-mycobacterial activity. A summary ﬂow chart showing
the approach used for hit follow-up is illustrated in Figure 3.
1st Campaign (hit series selected: pyrimidineimidazoles and
imidazopyridines): 106 CFU/ml of M. bovis BCG was incubated with
2 million compounds for 2 days in a 7H9 medium supplemented
with 10% ADS (albumin, dextrose and sodium chloride), 0.2% glyc-
erol and 0.02% Tween 80. Bacterial growth inhibition in presence of
compounds was measured using ATP as a surrogate marker. This
resulted in a 0.27% hit rate, with 5000 compounds showing
>35% inhibition at 10 lM concentration. After deprioritizing fre-
quent hitters and compounds containing undesirable functionalRecept
hERGbin
P
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Figure 3. Flow chart for follow-up activities towards a pre-clinical candidate. (MDR
interaction.)groups,22 the remaining compounds were tested for cytotoxicity
against Huh7 (human hepatocarcinoma) cells. Compounds with
selectivity index >10 (SI = CC50/MIC50) were selected for further
follow up. Reconﬁrmation by dose–response examination resulted
in 1000 conﬁrmed hits with minimum inhibitory concentration
(MIC50) <10 lM against Mtb H37Rv.
2nd Campaign (hit series selected: pyrazolopyrimidines and indol-
carboxamides): This screen was conducted to enhance the pool of
starting points and enrich for slower acting hits. A lower cell den-
sity M. bovis BCG culture (105 CFU/ml) was incubated with test
compounds for 4 days in a 7H9 medium. As expected, the initial
hit rate increased to 0.79% with 4 days of drug exposure, compared
to 0.27% with 2 days exposure. Similar ﬁlters to the 1st campaign
were applied and non-glycerol dependence of activity conﬁrmed.
3rd Campaign (hit series selected: pyridones): The ﬁrst 2 HTS cam-
paigns had signiﬁcantly high attrition rates during conﬁrmation of
glycerol independent activity (11%) and also M. bovis BCG versus
Mtb H37Rv evaluation (20%). In the third campaign 2.2 million
compounds were screened directly against Mtb H37Ra avirulent
strain (105 CFU/ml), in a 7H9 medium without glycerol with 4 days
exposure. This screen yielded 14,500 actives at a hit rate of 0.92%
(>35% inhibition at 10 lM). This included 5600 compounds
previously identiﬁed in the BCG campaigns.
A total of 2286 compounds with MIC50 <10 lM versus Mtb
H37Rv were identiﬁed from the 3 screens.
4. Lessons learnt from the phenotypic screens and during
follow-up of hits
4.1. Limited number of good starting points for follow-up
Despite the huge effort described above, the number of highly
potent and novel anti-mycobacterial compounds identiﬁed wasB. Lead Optimization activities
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Mtb H37Rv made up only 7% of 2286 hits (Fig. 2)). Removing
known anti-TB chemotypes, highly lipophilic compounds and large
natural product molecules reduced this to <1%. The majority of the
hits (75%) showed only modest in vitro anti-mycobacterial activ-
ity in the 1–10 lM range. This is in marked contrast to the ﬁndings
in malaria phenotypic screening where a much higher proportion
of the initial blood stage phenotypic malaria hits were active in
the sub-micromolar range23–25 and it may indirectly reﬂect the
reduced permeability of the mycobacterial cell wall which limits
access of many compounds to intracellular targets.26,27
A signiﬁcant proportion of the conﬁrmed hit compounds were
found to be structurally related to existing TB drugs or chemotypes
already known to display anti-mycobacterial activity. For example,
in the 2286 H37Rv hit list, there were 285 acyl hydrazides (related
to INH); 239 nitro aromatics (related to PA824); 242 thiosemicar-
bazones; 25 analogues of p-aminosalicylic acid and 15 thioureas.
All of these familiar chemotypes were eliminated from further con-
sideration. Typical medicinal chemistry triaging ﬁlters, analogous
to those that have been previously applied and extensively detailed
elsewhere in the literature were then applied to the remaining
hits.22,25 Using some simple yet stringent lead-like criteria on lipo-
philicity, size and potency (c logP <4, Mwt <450, MIC50 <5 lM) led
to a further drastic reduction in the number of potentially interest-
ing compounds to select from (e.g., in the H37Rv set of 2286 con-
ﬁrmed actives, only 205 compounds with no previously reported
anti-mycobacterial structural features passed the above criteria).
In summary only 42 ﬁltered hits were active below 1 lM with
LipE >3 (calculated fromMtb H37Rv MIC50). Our overall experience
was that only a very small proportion of the TB phenotypic screen-
ing hits had ideal lead-like characteristics that would generally be
sought by medicinal chemists looking to initiate optimisation to
discover oral drug candidates.
Further preliminary SAR generation around promising hits
(through testing additional available analogues) and broader pro-
ﬁling (e.g., measuring physicochemical properties such as logD,
metabolic clearance in microsomes, aqueous solubility, etc.)
allowed the ﬁnal prioritisation and selection of scaffolds for medic-
inal chemistry follow up. Since the anti-mycobacterial screening
was carried out in several campaigns, this process was repeated
several times and by different chemists applying their own per-
sonal criteria/judgments. A number of series were pursued brieﬂy,
but abandoned at an early stage due to insurmountable challenges.
These included a lack of clear SAR (where signiﬁcant structural
changes led to a range of analogues all with similar activity or inac-
tive), inability to increase activity over the initial hit, Mtb activity
linked to general cytotoxicity, etc. Eventually, from the hit to lead
work carried out over 7 years, 5 chemical series were selected for
more extensive optimization efforts. The structures of the hit and
the eventual optimised compound from each of these series are
summarised in Table 2.
4.2. Medicinal chemistry strategy for lead optimisation is
empirical/synthesis driven
It is a signiﬁcant challenge for medicinal chemists to interpret
structure–activity relationships in a cell based lead optimization.
Changes in cell permeability/efﬂux of the compound may modu-
late activity in addition to any changes in target engagement.
Hence, phenotypic lead optimisation can be difﬁcult and chemistry
approaches tend to be largely empirical and driven by feasibility of
synthesis.
Optimisation efforts in the NITD TB programme were very
much conducted in this manner, but with emphasis placed on try-
ing to manage physicochemical properties within each series to
identify analogues with the best possible balance between potencyand developability properties. The following sections outline some
of the ﬁndings and lessons learned on the 5 series highlighted
above.28–34
4.3. Ensure the appropriateness of growth media
(pyrimidineimidazoles)
A cluster of 5 pyrimidine imidazoles with MIC ranging from
0.11 to >20 lMwas identiﬁed in the ﬁrst HTS campaign. 300 ana-
logues were synthesised during optimisation of this series, which
eventually resulted in identiﬁcation of two advanced bactericidal
compounds NITD-501 and NITD-372 with potent in vitro activity
(Fig. 4A).28 At 25 mg/kg oral dose both compounds reached lung
exposure above MIC50 for 30–100% of the dosing interval
(Fig. 4B). Furthermore, dose linearity in exposure was demon-
strated up to 100 mg/kg. Despite the favourable in vitro potency
and pharmacokinetic properties, however, both compounds failed
to show in vivo efﬁcacy in the acute mouse TB model up to
100 mg/kg after 4 weeks oral dosing (Fig. 4C). Subsequently it
was discovered that the in vitro anti-TB activity of this class of
compounds is dependent on the presence of glycerol in the growth
medium, and with glucose as a sole carbon source, Mtb was resis-
tant to both NITD-372 and NITD-501 (Fig. 4D). It has now been pro-
posed that the in vitro bactericidal activity of pyrimidine-
imidazoles in presence of glycerol is driven by the generation
and accumulation of methyl glyoxal, a reactive cytotoxic metabo-
lite formed during the breakdown of glycerol in mycobacteria.
Pyrimidine imidazoles potentially interfere with the methyl gly-
oxal detoxiﬁcation pathway, leading to accumulation of methyl
glyoxal (Fig. 4E). Since glycerol is not a carbon source utilised by
Mtb in vivo, this mechanism explains the lack of efﬁcacy observed
in the mouse model.
Historically, the culture media used for NCE testing were all
developed empirically for optimal propagation of Mtb bacilli
in vitro from patients sputum samples and not optimised for drug
screening, Nor were they meant to reproduce the conditions
encountered by Mtb in the infected host. Re-evaluation of other
in house hits revealed that this phenomenon was not unique to
the imidazopyrimidine series and that other chemotypes also dis-
played glycerol dependent activity. Similar glycerol dependent
active hits have been found by several other groups.35 As a result
of this, the assay conditions at NITD were modiﬁed (7H9 medium
without glycerol) to reconﬁrm glycerol-independent activity
against Mtb. This observation reiterates the importance of validat-
ing the relevance of in vitro assay conditions to a disease state in
animal models and in patients.
4.4. Bacteriostatic compounds show poor in vivo efﬁcacy
The second promising hit series pursued was the imidazopyri-
dine class, which was identiﬁed in the M. bovis BCG screen. The
imidazopyridines have also been identiﬁed in phenotypic screen-
ing and optimised by several other TB research groups.29,36–38 This
class is very attractive as a starting point for lead optimisation
since it has several desirable features, like potent anti-TB activity,
acceptable lipophilicity and the prototype compounds are small
and chemically simple to utilise parallel synthesis to rapidly
develop SAR. During the optimisation of this series, around 300
compounds were prepared and proﬁled for their anti-mycobacte-
rial activity in vitro. In addition to improving in vitro potency, lead
optimisation efforts improved metabolic stability and aqueous sol-
ubility, which led the identiﬁcation of IPA4 (MIC50 10 nM and
c logP 4) for further in vivo proﬁling (Table 2).
Despite the promising plasma exposure in mouse, IPA4 showed
very weak activity in the mouse acute efﬁcacy model with only
1log reduction in lung bacterial load after 4 weeks of daily dosing
Table 2
Phenotypic TB hit series followed up
Initial hit MIC50
(lM)
c logP (M
wt)
LipEe Optimised compound MIC50
(uM)
c logP (M
wt)
LipEe Comments/reference/Status
Pyrimidinylimidazole
N
N
N
NH
N
H
N
HN
O
1.0a 3.2 (363) 2.8
O N
N
N
N
NH
N
H
N
O
NITD-501
0.04a 2.9 (419) 4.5
300 NCEs synthesised
Terminated series
- Glycerol dependent cellular
activity.28
- No in vivo efﬁcacy
Imidazopyridine
N
N
H
NO
0.2 3.1 (300) 3.6 N
N
H
NO
N
IPA4
0.01 4.0 (356) 4.0
300 NCEs synthesised
Terminated at NITD
- Bacteriostatic
- Lack of in vivo efﬁcacy
- Q203 (IPKc) to pre-clinical
development.29
- QcrB inhibitor
Indolcarboxamide
N
H
HN
O 0.8 4.5 (270) 1.6 Cl
Cl
N
H
HN
O
NITD-304
0.02 6.1 (339) 1.6
280 NCEs synthesised
- Preclinical candidate30,31
- MmpL3 inhibitor
Pyrazolopyrimidineb
CF3
H
N
N N
H
N
O
1.9 3.2 (414) 2.5
CF3
(R)
(S)
H
N
N N
H
N
O F
NITD-192
0.2 3.3 (432) 3.4
450 NCEs synthesised
Terminated series
- Good efﬁcacy,32 but limited
maximum exposure
- Development hurdle
- MmpL3 inhibitor
4-OH Pyridones
N
H
O
OH
NITD-529 
2.2 3.0 (243) 2.7 NH
O
O
R
NITD-916: R = H
(Pro-drug: R =CH2OP(O)(OH)2 )
0.03 5.3 (311) 2.2
80 NCEs synthesised
Promising lead series
- KatG independent InhA
inhibitor33,34
- Potential starting point for
SBDDd
a MIC50 determined in glycerol containing assay medium.
b For this series, measured logP is signiﬁcantly higher than c logP by 2.5–3 log units.
c Institute Pasteur Korea.
d SBDD structure based drug design.
e LipE: = pMIC50 – logP.
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microbiological proﬁling of IPA4 showed it to be a bacteriostatic
compound (minimum bactericidal activity >10 lM), possibly
explaining the weak in vivo activity. In light of these results, to
reduce the risk of failure in animal models, we subsequently
focused efforts onto series which displayed potent in vitro bacteri-
cidal activity. It is interesting to note that optimization of imidazo-
pyridines by Qurient Incorporated, Korea led to the identiﬁcation
of highly lipophilic compound Q-203 (c logP 7.62) with a promising
in vivo efﬁcacy.29,37
4.5. Relationship between anti-mycobacterial potency and
lipophilicity
In common with most lead optimisation efforts, an important
driver for the medicinal chemistry in all ﬁve series was the desire
to introduce structural features to enhance potency against Mtb. As
shown in Figure 5 this proved challenging with only a small pro-
portion of analogues achieving MIC50 <100 nM. This contrasts with
our experience optimising phenotypic blood stage malaria hits
(where attaining low nM whole cell active compounds proved
much less difﬁcult)39,40 and may again reﬂect the reduced perme-
ability of the mycobacterial cell wall.26,27 One third (by dry mass)
of the mycobacterial outer envelope consists of mycolic acids,which are exceptionally long a-branched b-hydroxy fatty acids
with up to 90-carbon chain length and it acts as an extremely
efﬁcient permeation barrier. In general, increasing the anti-
mycobacterial potency within each series was accompanied with
a substantial increase in logP (Fig. 5). Signiﬁcant improvements
in LipE were rarely observed. A recent report highlighted the
tendency for logP to increase during early discovery (median logP
of HTS hit 3.8 increased to 4.1 in advanced leads).41 The increase in
logP seems to be even more pronounced in optimization of TB
phenotypic screening hits (Table 2 and Fig. 5B).
Based on multiple retrospective physicochemical properties
analyses of NCEs, lipophilicity is recognised to impact on a number
of drug-like futures including PK and toxicology properties.42 High
lipophilicity is also strongly linked to off-target promiscuity.43
Therefore, challenges in drug development due to low solubility
and increased risk of safety are often encountered with highly lipo-
philic compounds (to be discussed in the following sections with
example). This is an important point to be considered when select-
ing future starting points for lead optimisation from TB phenotypic
screens. Based on our experience, hits with low micromolar
activity and moderate to high c logP (>4) will most likely be very
challenging to transform into potent developable drug candidates.
Using LipE based on MIC50 to guide initial phenotypic hit selection
is therefore recommended.
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Figure 5. (A) Relationship between potency and lipophilicity for four scaffolds. The hit and the lead candidate in each of the series are shown (green dots). Inactive/weakly
active NCEs (MIC50 >10 lM) not shown. Chemical space occupied by representative TB drugs (MIC50 <1 lM and c logP <3) are shown in box. (B) Average c logP and anti-TB
potency of initial hits and optimised compounds.
Figure 4. Importance of growth medium for phenotypic screening, a case study with pyrimidineimidazoles.
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(pharmacokinetic–pharmacodynamic) relationships are poorly
understood
The indolcarboxamide and pyrazolopyrimidine series were
selected from the second HTS. Similar to the imidazopyridines,both have attractive features as starting points for lead optimisa-
tion since they are small and structurally simple, requiring
straightforward synthesis to develop SAR. Around 300 compounds
were synthesised in the indolcarboxamides, 450 in the pyrazolo-
pyrimidine series.30,32 It is noteworthy that both of these series
have also been recently identiﬁed as hits from phenotypic
U.H. Manjunatha, P.W. Smith / Bioorg. Med. Chem. 23 (2015) 5087–5097 5093screening efforts by other TB researchers.20,44 Importantly, proto-
type compounds from both classes were shown to be cidal
in vitro and medicinal chemistry optimisation led to the discovery
of analogues combining good in vitro anti-mycobacterial activity
with favourable mouse pharmacokinetic proﬁles. Indolcarboxamide,
NITD-304 displayed low total systemic clearance (18.1 ml
min1 kg1), high volume of distribution in mouse (4.1 L kg1)
with elimination half-life 5.1 h and good oral bioavailability
(>50%). This translated to excellent in vivo efﬁcacy in the acute
mouse TB model.31
In the pyrazolopyrimidine series, we made substantial efforts to
improve the poor physicochemical properties of the optimised
compound NITD-192 and successfully synthesised several less
lipophilic analogues with similar in vitro anti-mycobacterial activ-
ity (compounds 1–3 in Fig. 6). These analogues all had lower c logP,
lower plasma protein binding (PPB) and favourable in vivo PK
properties in mouse (AUC0–24hPNITD-192) and were proﬁled in
the mouse efﬁcacy model. However, whilst NITD-192 produced a
3.5log CFU reduction in this model, compounds 1–3 did not dem-
onstrate any efﬁcacy at the same dose.32 Although we have not yet
clearly understood the reason behind the lack of efﬁcacy, the
shorter half-lives, lower volume distributions and lower lung to
plasma distribution of 1–3 (Fig. 6) may impact adversely on lung
exposure which is the primary site of Mtb infection.
Overall, these results highlight the fact that our present level of
understanding of the PK–PD relationships driving efﬁcacy in the TB
mouse model are limited and future work is still required to gain
more insight in this area.45 Our current thinking is that it may be
more informative to correlate drug concentrations in the lung or
lung epithelial lining ﬂuid with efﬁcacy.46
4.7. Development challenges for efﬁcacious lipophilic
compounds
The major challenge encountered in optimising lipophilic series
is to balance the desirable sub-micromolar anti-mycobacterial
activity with favourable physicochemical properties. As high-
lighted above, maximising potency in pyrazolopyrimidines and
indolcarboxamide series led to synthesis of highly lipophilic mole-
cules. The analogues ultimately selected for in vivo evaluation hadFigure 6. Understanding PK–PD relationship is important for covery low aqueous solubility (<10 lM) and consequently required
development and use of non-routine microemulsion pre-
concentrate (MEPC) formulations in order to evaluate them in
efﬁcacy studies at high doses. With an MEPC formulation it was
possible to attain good exposure levels of NITD-304 in mice,
resulting in an excellent in vivo efﬁcacy.31 The minimum efﬁca-
cious dose for the advanced lead pyrazolopyrimidine NITD-192
was 100 mg/kg.32 In order to progress a new drug candidate for
TB it is necessary to establish a wide margin of safe exposure
(ideally >10-fold) above the efﬁcacious level. However, at higher
doses, the maximum exposure multiple that could be achieved
with NITD-192 was <3 fold. Additional attempts to increase
exposure with other specialised formulations (solid dispersion
and nano suspension) were unsuccessful (Lakshminarayana et al.
unpublished results) and further progression of the compound into
pre-clinical evaluation was not possible.
This example with NITD-192 illustrates the point that optimis-
ing hits into lipophilic chemical space will most likely introduce
substantial hurdles and challenges for drug development and
highlights the importance of focusing attention on managing
physicochemical properties as much as possible during lead
optimisation. It must be noted, however, that recently approved
MDR TB drug bedaquiline has a c logP of 6.41 with a Mw 555 Da
and also that there are other promising lipophilic TB candidates
in clinical development with high c logP (OPC67683, 5.2; SQ109,
5.8). Thus it appears that despite obstacles it may be possible to
develop compounds with poor properties.
In order to try to minimise such developmental challenges, the
4-hydroxy 2-pyridone series was selected from the 3rd HTS (prom-
ising hit NITD-529 c logP 3.0, Mw 243 and MIC 2.2 lM).27 However,
in order to increase in vitro anti-mycobacterial activity, in this
series it was again necessary to increase lipophilicity (optimised
compound NITD-916, c logP 5.3 and MIC 0.03 lM) (Table 2).34
NITD-916, again needed to be dosed in a micro-emulsion formula-
tion to successfully achieve efﬁcacious exposure. Improving
aqueous solubility is critical to move away from a lipid-based for-
mulation and also to de-risk clinical development of the drug.47
Phosphate-ester pro-drugs have been used to enhance aqueous
solubility to allow a more favourable oral administration and are
generally rapidly hydrolysed by intestinal alkaline phosphatases.48mpound selection, a case study with pyrazolopyrimidines.
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NITD-916 (Table 2) improved aqueous solubility by >100-fold
and achieved efﬁcacious exposure dosed from a simple methyl
cellulose suspension. Further, MoA studies and a high-resolution
co-crystal structure of NITD-916 with its molecular target (inhA)
has opened up the possibility for future structure-based rational
lead optimization of this series.33 Applying a similar pro-drugging
approach may also be possible for other series.
4.8. Multiple diverse chemotypes target membrane bound
proteins including promiscuous targets mmpL3, drpE1 and qcrB
Recently, multiple TB research groups have reported successful
identiﬁcation of compounds active against tuberculosis using
whole cell screening approach.20,29,31,35,49,50 Further, in order to
understand the mechanism of action, spontaneous resistance
mutants were generated and potential targets were identiﬁed
using whole genome sequencing approach. Mmpl3, DprE1 and
QcrB emerged as most common targets, in spite of compounds
belonging to structurally diverse classes (Fig. 7).
Resistance conferring mutations were mapped to Mmpl3 for
both pyrazolopyrimidine and indolcarboxamides.31,32 Mmpl3 is
an essential membrane transporter belonging to resistance, nodu-
lation, and division (RND) family, present in the outer membrane
mycobacteria and is responsible for transporting trehalose mono-
mycolates to envelope for biosynthesis of mycolic acids. Mutations
in Mmpl3 have also been observed in resistant mycobacterium to a
number of other recent structurally diverse anti-mycobacterial
compounds like SQ109,51 adamantyl urea derivative AU1235,52
pyrrole derivative BM212,53 benzimidazole,35 THPP, spiro ana-
logs,54 and indolcarboxamides.44,55 It is intriguing that such diverse
chemical structures all potentially inhibit MmpL3 and most of the
resistance mutations are mapped to the transmembrane regions of
the protein. The apparent common feature of all the compounds is
that they are highly lipophilic (c logP >4.2) and either neutral or
basic. Nearly half of the reported MmpL3 inhibitors contain lipo-
philic non-aromatic substituents such as adamantine or cycloalkyl
moieties. These ﬁndings have led us to hypothesize that the ligand-
binding portion of MmpL3 is a large hydrophobic pocket that
accommodates neutral or basic lipophilic compounds; however,
this requires further experimental validation.
DprE1 is another membrane associated target that has been tar-
geted by diverse set of compounds namely the benzothiazinones,Figure 7. Phenotypic hits predominantly target membrane bound proteins like
mmpL3, ATP synthase, drpE1 and qcrB.dinitrobenzamides, dinitro substituted triazoles, azaindole deriva-
tives, amino-quinolone piperidine amides, pyrazolopyridones and
TCA1.56–62 DprE1 is an essential membrane-associated enzyme
subunit of the heteromeric decaprenylphosphoryl-b-D-ribose-
epimerase involved in biosynthesis of D-arabinose, which is a sub-
strate for synthesis of arabinogalactan and lipoarabinomannan.
Although the co-crystal structure of DrpE1 with BTZ and TCA1
has been solved and structural basis of compound interaction has
been elucidated,62,63 questions remain why this target is preferred
by multiple chemically diverse scaffolds.
Similarly, respiratory targets such as ATP synthase and QcrB are
other membrane targets that have been characterised by raising
resistance mutants against compounds identiﬁed by whole cell
screening. Bedaquiline targets AtpE, whilst the Q203 and imidazo-
pyrimidine series is known to target QcrB.29,36,64 AtpE is an essen-
tial part of F0 in multi-protein complex of ATP synthase essential
for production of ATP. QcrB is a putative ubiquinol cytochrome c
reductase (subunit b), an integral membrane protein and member
of the bc1 complex in electron transport chain. Both these proteins
are membrane bound proteins, once again necessitating relatively
hydrophobic compounds to inhibit them.
Phenotypic screening in TB thus appears to select for many
membrane bound targets, suggesting a bias of WCS hits potentially
due to highly lipid-rich cell wall.50 Repeated identiﬁcation of muta-
tions in membrane proteins for many of the novel compounds
identiﬁed from whole cell screening approach may also suggest
that they may be using them as way to enter into the mycobacte-
rial cells and the actual target could be different for different
scaffolds inside the mycobacterial cells.62,65 Otherwise, it is also
possible that some of these compounds could be just membrane
potential disruptors thereby nullifying proton motive force and
collapsing the ionic balance leading to death of mycobacterial
cells.66 It is highly critical to understand the potential molecular
target early in the drug discovery cascade by analysing cross-resis-
tance with various mutants or by other MoA studies, thus de-risk-
ing optimizing multiple leads with the same MoA.5. Practical perspective to facilitate future phenotypic screening
and selecting new hits for optimization
5.1. Expanding chemical space
Studying the compounds in Table 2 it is evident in all series that
the structural differences between the initial hits and phenotypi-
cally optimised compounds are relatively small, that is, modest
structural changes were sufﬁcient to improve potency and opti-
mise PK properties. Similar observation was also made in whole
cell based lead optimization of antimalarials.39 In the absence of
any molecular target’s structural information to guide medicinal
chemistry, more speculative and signiﬁcant structural changes
invariably resulted in complete loss of anti-mycobacterial activity.
It is thus evident that in phenotypic optimisation, selection of the
starting points for chemistry is extremely critical, and will likely
have the greatest impact on the ﬁnal outcome of the project. As
we have observed the increase in anti-mycobacterial potency
was frequently achieved only through increasing lipophilicity,
hence ﬁnding small hydrophilic hits with good activity against
Mtb should offer the best possible starting points for future
success.
Antibacterial drugs in general are known to occupy a unique
physicochemical space.67 In order to further anticipate where
future success may be found, it is also informative to examine
the properties of the existing TB drugs.68 Many of the TB drugs
occupy a unique chemical and property space like small and polar
(isoniazid, PZA, Ethionamide, PAS, etc.), large complex polar
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sides, capreomycin, etc.), reactive and covalent binders (isoniazid,
ethionamide, PAS, PZA) and highly lipophilic molecules (clofazi-
mine, bedaquiline). Of particular note here is the observation that
many are small and hydrophilic molecules, initially this seems
slightly counter-intuitive since the mycobacterial cell wall is
highly lipophilic in nature.26,27 However, it can be speculated that
the small and polar nature may enable the molecules to by-pass
the mycobacterial cell wall via the same hydrophilic channels that
must allow access to polar nutrients.69 Thus, molecules which are
small and hydrophilic may have a very good chance to permeate
mycobacteria and reach their site of action.
Another important observation is that many of the anti-
mycobacterial drugs, especially the small and polar molecules,
are pro-drugs that are speciﬁcally activated within the mycobacte-
rial cell.70 The possibility of ﬁnding new compounds working in
this way was essentially precluded in our programme since our
hit triaging intentionally removed potentially reactive groups and
chemotypes known to require bioactivation. Since the activation
coupled with covalent binding strategy is historically proven with
isoniazid and ethionamide, it is still an option to be seriously con-
sidered in future TB discovery efforts. It is interesting to note that
one of the recently reported promising drug candidates BTZ043
(benzothiazinone) is a prodrug and a covalent inhibitor of DprE1.71
Owing to the fact that natural products have apparently been
shaped by evolution and occupy an unexplored large chemical
space, they still appear to be a promising source of the antibiotics.
The success of natural products and natural product derivatives as
therapeutics is particularly high (78%) in the area of infectious
diseases.72 With the recent developments in the natural product
synthesis and advanced bio-analytical capabilities, natural prod-
ucts screen in combination with metabolic engineering, synthetic
biology and techniques for total synthesis of complex secondary
metabolites, offer promising avenues.73 Recent structural studies
of various natural products such as rifampicin, lipiarmycin, myxo-
pyronin, spectinamides, capreomycin, cyclomarin and viomycin
have not only helped to elucidate mechanistic details of complex
macromolecular processes but have also facilitated rational struc-
ture based design.74–77 Thus natural products do offer promising
starting points for rational medicinal chemistry.
5.2. Expanding molecular target/pathway space
Target based biochemical screens often fail to exhibit cellular
activity, while large scale cell-based phenotypic screening often
results in a very few promising hits. In general medicinal chemists
can improve molecular target enzyme activity using rational
design. However, it is a daunting task to improve penetration of
small molecules into Mtb cells until we deﬁne a set of physico-
chemical properties required for Mtb cell wall permeability. To
tap into the best of both worlds, that is, target-based and cell-
based strategies, a ‘target-speciﬁc’ cell based screen has been
developed.17,78–81 In these assays conditional mutant strains that
under-express a gene of interest is used for whole cell screening,
thus making a hyper-susceptible strain to a particular target or
pathway. In addition to identifying a potential molecular target,
because of the hypersensitive nature of these strains, ‘target-
speciﬁc’ WCS also help in identifying new lead compounds that
would not have been possible in traditional cell-based screens.79
By this approach, any newly deﬁned potential target can be
screened for inhibitors, with the deﬁned biochemical activity.
As described in this manuscript, considering the challenges
faced during lead-optimization of phenotypic hits (like lipophilic-
ity driven cellular potency) and consequent clinical development
hurdles (like exposure limited therapeutic safety margin), it is
important to invest effort in molecular target identiﬁcation tostrive to integrate biochemical assays during lead-optimization
and SAR interpretation. However, knowing the complex mode of
antibiotics action in cells and considering the uncertainties
involved in elucidating the mechanism of action, molecular target
identiﬁcation efforts are not on the critical path of lead optimiza-
tion. Biological clustering of hits early in the discovery stage would
be quite helpful in expanding molecular target/pathway space.
This can be based on cross-resistance to promiscuous targets
mutants (mmpL3, dprE1, qcrB, etc.) or using a pathway speciﬁc
inducible reporter strains or activity against a panel of conditional
mutant strains. Biological clustering would also help in de-risking
the drug discovery portfolio with investments in diverse molecular
targets/pathways and also to keep track of on-target effect of hits
during lead-optimization.
6. Conclusions
Despite the urgency and massive worldwide efforts to ﬁnd
novel tuberculosis drugs, progress is still limited and the chal-
lenges confronted by drug discovery scientists remain formidable.
Overall success with phenotypic screens is much better than target
based biochemical screening strategy. Our experience suggests
that expanding chemical diversity in conjunction with expanding
the molecular target space strategy would provide a means to
identify novel targets and also deliver new chemical entities to
the clinic. Our experiences over 7 years of phenotypic screening
and lead-optimization of multiple scaffolds highlight many obsta-
cles and offer some ways forward.
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